Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, EyePoint Pharmaceuticals Inc’s stock clocked out at $6.13, up 7.17% from its previous closing price of $5.72. In other words, the price has increased by $7.17 from its previous closing price. On the day, 1.12 million shares were traded.
Ratios:
To gain a deeper understanding of EYPT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.79 and its Current Ratio is at 7.85. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on January 07, 2025, initiated with a Buy rating and assigned the stock a target price of $33.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on August 28, 2024, with a $15 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 15 ’25 when Zaderej Karen L. bought 5,000 shares for $5.47 per share. The transaction valued at 27,350 led to the insider holds 26,500 shares of the business.
Zaderej Karen L. bought 5,000 shares of EYPT for $27,100 on May 14 ’25. The Director now owns 21,500 shares after completing the transaction at $5.42 per share. On Oct 23 ’24, another insider, ANTHONY P. ADAMIS, who serves as the Director of the company, bought 67,100 shares for $10.04 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 7.53 while its Price-to-Book (P/B) ratio in mrq is 1.41.
Stock Price History:
Over the past 52 weeks, EYPT has reached a high of $13.98, while it has fallen to a 52-week low of $3.91. The 50-Day Moving Average of the stock is 1.34%, while the 200-Day Moving Average is calculated to be -22.24%.
Shares Statistics:
A total of 68.81M shares are outstanding, with a floating share count of 59.83M. Insiders hold about 13.36% of the company’s shares, while institutions hold 96.92% stake in the company.
Earnings Estimates
The stock of EyePoint Pharmaceuticals Inc (EYPT) is currently being evaluated by 10.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.55 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$2.05 and -$2.05 for the fiscal current year, implying an average EPS of -$2.05. EPS for the following year is -$2.79, with 11.0 analysts recommending between -$1.35 and -$2.96.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $6.82M. It ranges from a high estimate of $13M to a low estimate of $6.82M. As of the current estimate, EyePoint Pharmaceuticals Inc’s year-ago sales were $9.48MFor the next quarter, 11 analysts are estimating revenue of $7.85M. There is a high estimate of $13M for the next quarter, whereas the lowest estimate is $7.85M.
A total of 13 analysts have provided revenue estimates for EYPT’s current fiscal year. The highest revenue estimate was $66M, while the lowest revenue estimate was $29.03M, resulting in an average revenue estimate of $39.99M. In the same quarter a year ago, actual revenue was $43.27MBased on 13 analysts’ estimates, the company’s revenue will be $19.6M in the next fiscal year. The high estimate is $57.86M and the low estimate is $17.85M.
